Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
暂无分享,去创建一个
Andreas Hoeft | A. Hoeft | N. Nussmeier | J. Parlow | Steven W Boyce | A. Whelton | Nancy A Nussmeier | S. Boyce | R. Langford | Mark T. Brown | K. Verburg | Richard M Langford | Mark T Brown | Andrew A Whelton | Joel L Parlow | Kenneth M Verburg
[1] K. Schrör,et al. Aspirin resistance after coronary artery bypass grafting. , 2001, The Journal of thoracic and cardiovascular surgery.
[2] J. Couzin. Halt of Celebrex Study Threatens Drug's Future, Other Trials , 2004, Science.
[3] B. Lucchesi,et al. Mechanisms of myocardial reperfusion injury. , 1999, The Annals of thoracic surgery.
[4] S. Talwalker,et al. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. , 2001, Clinical therapeutics.
[5] G. Joshi,et al. Effective Treatment of Laparoscopic Cholecystectomy Pain with Intravenous Followed by Oral COX-2 Specific Inhibitor , 2004, Anesthesia and analgesia.
[6] W. Karzai,et al. Aspirin and mortality from coronary bypass surgery. , 2003, The New England journal of medicine.
[7] P. Duke,et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.
[8] J. Vincent,et al. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. , 1997, Chest.
[9] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[10] M. Buckley,et al. Thromboxane and prostacyclin changes during cardiopulmonary bypass with and without pulsatile flow. , 1982, The Journal of thoracic and cardiovascular surgery.
[11] G. FitzGerald. Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.
[12] RomanJaeschke,et al. Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib , 2002 .
[13] J. Gross. Parecoxib Sodium, a Parenteral Cyclooxygenase 2 Selective Inhibitor, Improves Morphine Analgesia and is Opioid-Sparing Following Total Hip Arthroplasty , 2004 .
[14] J. Grotta,et al. Shear-Induced Platelet Aggregation in Normal Subjects and Stroke Patients , 1995, Thrombosis and Haemostasis.
[15] W. Ray,et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease☆ , 2003 .
[16] E. Salzman,et al. Elevated Plasma Fibrinopeptide A ana Thromboxane B2 Levels During Cardiopulmonary Bypass , 1980, Circulation.
[17] M. Lamy,et al. Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans. , 1986, The Journal of thoracic and cardiovascular surgery.
[18] C Michael Stein,et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.
[19] David Lee Gordon,et al. Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.
[20] D. Mangano,et al. Renal Dysfunction after Myocardial Revascularization: Risk Factors, Adverse Outcomes, and Hospital Resource Utilization , 1998, Annals of Internal Medicine.
[21] I. Gilron,et al. Cyclooxygenase-2 Inhibitors in Postoperative Pain Management: Current Evidence and Future Directions , 2003, Anesthesiology.
[22] Robert Riddell,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[23] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[24] K. Schrör,et al. Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery , 2003, Circulation.
[25] C. Patrono,et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[26] W. Vaughn,et al. Perturbations in laboratory values after coronary artery bypass graft surgery with cardiopulmonary bypass. , 2005, Journal of cardiothoracic and vascular anesthesia.
[27] Marc A Pfeffer,et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.
[28] J. W. Schaeffer,et al. ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .
[29] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors☆ , 2002 .
[30] G. Smith,et al. Analgesic effects of parecoxib following total abdominal hysterectomy. , 2003, British journal of anaesthesia.